Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 30, 2025
Daily News
July 30, 2025
- MHLW to Link GS1 and YJ Codes in Public Database, Launch Planned for FY2028
July 30, 2025
- Gene Therapy Deaths Spur Strategic Rethink among Biotechs, Merck Exec Notes Investor Caution
July 30, 2025
- MHLW Raises Drug R&D, Supply Stability as FY2026 Budget Priorities
July 30, 2025
- Otsuka Ups H1 Earnings Outlook on Rexulti, Other Global Brands
July 30, 2025
- Lenvima Bolsters Label for HCC in China: Eisai
July 30, 2025
- NCVC-Backed Startup Raises US$14 Million to Develop PAH Therapy
July 30, 2025
- Rakuten Launches Japan Arm of Global PIII for Photoimmunotherapy/Keytruda Combo
July 30, 2025
- Toa Eiyo Scraps TGCV Drug CNT-01 after Japan PIIb/III Miss
July 30, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…